Tesamorelin
For research use onlyCAS 218949-48-5
A synthetic growth-hormone-releasing hormone (GHRH) analog research peptide.
Mass (mg)
Bundle & Save
Frequency
before 1:00 PM CT
money-back
on orders $50+
Stabilised GHRH analog. Tesamorelin is a synthetic 44-residue analog of growth-hormone-releasing hormone (GHRH), the hypothalamic peptide that signals at the anterior pituitary to control growth-hormone release. It reproduces the biologically active sequence of human GHRH(1–44) and carries an N-terminal modification, a trans-3-hexenoyl group on the first residue, that improves resistance to enzymatic degradation compared with the native hormone under study conditions. Brightly supplies it as a lyophilized (freeze-dried) powder in a sealed, tamper-evident vial, prepared and handled strictly as a characterised reference material for in-vitro laboratory research.
The characterisation below summarises the properties that define the material as supplied and set a stabilised analog apart from the native hormone sequence:
| Property | Characterisation |
|---|---|
| Origin | Fully synthetic analog of human GHRH(1–44) |
| Length | 44 residues |
| Molecular formula | C221H366N72O67S |
| N-terminal modification | trans-3-hexenoyl group; improves resistance to enzymatic degradation |
| Supplied form | Lyophilized powder, nitrogen-sealed vial |
Because each vial contains a single, defined sequence rather than a mixture, Tesamorelin gives researchers a consistent reference point for GHRH-receptor pharmacology and growth-hormone / IGF-1 axis studies. A characterised, lot-verified analog supports reproducible in-vitro and preclinical work, where variability in the test article would otherwise confound interpretation of receptor-signaling and endocrine data.
Supplied strictly as a characterised reference material for in-vitro and preclinical laboratory work, not for any diagnostic or therapeutic purpose.
| Peptide class | GHRH analog |
|---|---|
| Molecular formula | C221H366N72O67S |
| Molecular weight | 5135.9 g/mol |
| CAS number | 218949-48-5 |
| Sequence | 44-residue GHRH-analog chain (full sequence on the COA) |
| Purity | ≥99% (HPLC) |
| Form | Lyophilized powder |
| Quantity | 10 mg per vial |
| Testing | HPLC, endotoxin (LAL), microbial DNA (PCR), third-party |
| Documentation | Certificate of Analysis included |
| Storage | −20°C, protect from light |
| Application | Research use only |
Research overview
Tesamorelin is supplied as a characterised reference material for controlled in-vitro and preclinical laboratory work. It is synthesised and purified to industry-standard protocols, making it suitable for analytical testing, receptor-pharmacology studies, and experimental endocrine models. Every lot is verified by HPLC for purity and identity, with a lot-specific Certificate of Analysis included.
Research-grade standards behind each batch
- Synthesised via solid-phase peptide synthesis (SPPS)
- Purified using preparative HPLC
- Verified through analytical quality-control procedures
- Screened for endotoxins by LAL
- Identity confirmed by HPLC
Why researchers study Tesamorelin
Published endocrine literature describes stabilised GHRH analogs as tool compounds for probing the growth-hormone axis at its point of control, the pituitary somatotroph,1 which makes them of interest for studying how that axis is regulated under controlled conditions. Areas of scientific interest include:
- GHRH-receptor binding and selectivity studies
- Somatotroph signaling mechanisms
- Growth-hormone pulsatility and secretion models
- GH / IGF-1 axis feedback investigations
- Peptide disposition and enzymatic stability
- Comparative GHRH-analog pharmacology
GHRH-receptor signaling
Tesamorelin is characterised for activity at the GHRH receptor, a G-protein-coupled receptor expressed on the somatotroph cells of the anterior pituitary.
GHRH receptor. Expressed on anterior-pituitary somatotrophs; studied for Gs-coupled signaling that raises intracellular cyclic AMP and drives the synthesis and pulsatile release of growth hormone.
Growth-hormone / IGF-1 axis. Growth hormone released from the pituitary acts on peripheral tissues, including the liver, where it is studied for its association with insulin-like growth factor 1 (IGF-1) production; IGF-1 in turn forms part of the feedback that regulates the axis. These relationships are described strictly as areas of scientific interest observed in laboratory models, not as established effects.
Enzymatic stability. The N-terminal modification is studied for the resistance it confers against dipeptidyl peptidase-4 (DPP-4) cleavage relative to native GHRH, a property of interest in peptide-disposition research.
Stabilised analog vs native GHRH
| Characteristic | Tesamorelin (as supplied) | Native GHRH |
|---|---|---|
| Origin | Fully synthetic analog | Endogenous hypothalamic peptide |
| Sequence | Defined GHRH(1–44) analog | GHRH(1–44) and shorter active forms |
| N-terminal modification | trans-3-hexenoyl group | None |
| Enzymatic stability | Improved resistance to degradation | Rapidly cleaved by DPP-4 |
| Batch consistency | Lot-verified by HPLC and MS | Not standardised |
Reference. Müller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev. 1999;79(2):511–607.
Supplied strictly as a characterised reference material for in-vitro and preclinical laboratory work, not for any diagnostic or therapeutic purpose.
Every lot of Tesamorelin follows a controlled, pharma-grade workflow from synthesis to fulfilment, so the material stays consistent, pure, and stable.
- Cleanroom manufacturing
- Synthesised in controlled, low-contamination environments for batch-to-batch consistency.
- Verified HPLC-verified purity
- Purity confirmed by high-performance liquid chromatography (HPLC).
- Verified identity & purity
- Identity and purity confirmed by HPLC, and endotoxin by Limulus Amebocyte Lysate (LAL).
- Endotoxin-controlled
- Low endotoxin levels matter in sensitive cell-based and signaling studies, where inflammatory contaminants could confound results.
- Pharma-grade raw materials
- Synthesis begins with tested amino acids and validated reagents to protect molecular integrity.
- Lyophilized for stability
- Freeze-drying preserves structural integrity during shipping, storage, and handling.
- Nitrogen-sealed vials
- Vials are sealed under nitrogen to limit exposure to oxygen and moisture.
Understanding lyophilization. Freeze-drying removes moisture by freezing the material and lowering pressure so water sublimates directly from solid to vapour, leaving a stable, dry powder that tolerates storage well for long-term studies.
Before reconstitution. Unopened lyophilized Tesamorelin tolerates short periods at room temperature in a cool, dry place away from heat, humidity, and light. For longer storage, keep sealed vials frozen: −20 °C is common, while −80 °C adds margin for long-term or archival storage.
After reconstitution. Reconstitute with bacteriostatic water, then keep the solution refrigerated below 4 °C, aliquot to working volumes, and avoid repeated freeze-thaw cycles. Under appropriate laboratory conditions, reconstituted solutions typically remain stable for up to 30 days, following your own laboratory protocol.
- Same-day dispatch (USA)
- In-stock orders placed before 1:00 PM CT ship the same business day.
- Fast domestic delivery
- Free FedEx shipping on every order; express delivery is free on orders over $150.
- Protective handling
- Vials are held in temperature-controlled storage before shipment; the lyophilized powder is stable for ambient transit and is packed to limit temperature swings, moisture, and physical damage.
- Tracking and guarantee
- Tracking is provided at shipment, and every order is backed by our 30-day money-back guarantee.
For research use only. Not for human or animal consumption.
